History | Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | Guidance | NICE

History

A list of downloadable documents created during development.

Review proposal consultation

Review proposal consultation
Stakeholder matrix ^{MSWord 35 KB} 25 April 2016
Review proposal paper ^{PDF 249 KB} 25 April 2016

Background information

Press release information

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013 ^{PDF 169 KB} 24 May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination information
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document ^{PDF 291 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) ^{PDF 250 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): consultee and commentator comments on the ACD
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Roche Products ^{PDF 770 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome ^{PDF 101 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer ^{PDF 198 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing ^{PDF 24 KB} 22 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists ^{PDF 3.6 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO) ^{PDF 324 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Department of Health ^{PDF 22 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NHS outer north east London cluster ^{PDF 135 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service ^{PDF 315 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Southampton Health Technology Assessments Centre ^{PDF 30 KB} 25 March 2013
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): comments on the ACD received from the public through the NICE website ^{PDF 49 KB} 25 March 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation document information
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222) information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal announcement information
Appeals received ^{PDF 300 KB} 25 March 2015
Initial scrutiny letter - Pharma Mar ^{PDF 285 KB} 25 March 2015
Response to scrutiny letter ^{PDF 180 KB} 25 March 2015
Final scrutiny letter ^{PDF 104 KB} 25 March 2015
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (including reviews of technology appraisal guidance 91 and 222): notice of appeal information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report ^{PDF 2.29 MB} 23 December 2014
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination document ^{PDF 542 KB} 23 December 2014
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appraisal consultation information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appraisal consultation document information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report information
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report ^{PDF 10.74 MB} 27 September 2013
Ovarian Cancer Topotecan Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel Trabectedin and Gemcitabine (Review) Assessment Report - Consultation ^{PDF 6.08 MB} 22 July 2013
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final protocol ^{PDF 330 KB} 18 December 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final scope (post CIM) ^{PDF 67 KB} 12 February 2013
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final matrix ^{PDF 66 KB} 28 November 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and commentator comments on the draft scope ^{PDF 278 KB} 28 November 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): equality impact assessment form - scoping ^{PDF 29 KB} 28 November 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft scope ^{PDF 74 KB} 05 September 2012
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft matrix ^{PDF 66 KB} 05 September 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): evaluation report
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Pre-meeting briefing ^{PDF 528 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report ^{PDF 453 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report - factual accuracy check ^{PDF 57 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer submission - Roche ^{PDF 2.6 MB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Clarification
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NICE clarification letter ^{PDF 85 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer response to the NICE clarification letter ^{PDF 350 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Patient group, professional group and NHS organisation submission statements
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NCRI Gynaecological CSG/RCP/RCR/ACP/JCCO ^{PDF 282 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome ^{PDF 107 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovarian Cancer Action ^{PDF 100 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing ^{PDF 6.9 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists ^{PDF 52 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer ^{PDF 92 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Expert written personal statements
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Marcia Hall ^{PDF 38 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sharon Tate ^{PDF 45 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sarah Blagden ^{PDF 45 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Louise Bayne ^{PDF 26 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Rajinder Nijjar ^{PDF 52 KB} 18 December 2012
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Oge Chesa ^{PDF 40 KB} 18 December 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012 ^{PDF 47 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012 ^{PDF 129 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012 ^{PDF 51 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012 ^{PDF 55 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012 ^{PDF 46 KB} 29 June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope ^{PDF 47 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix ^{PDF 58 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix ^{PDF 39 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope ^{PDF 147 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment ^{PDF 44 KB} 16 September 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010 ^{PDF 48 KB} 11 February 2011

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010 ^{PDF 61 KB} 11 February 2011